Patent Legal Services

1/18/2022 Update: Amendment No. 4 with Additional Question-and-Answer is now uploaded. 1/14/2022 Update: A question has been received from a prospective offeror that the Government deems important enough to answer, in order to assist offerors in finalizing their proposals, that the proposal due date is hereby extended to 1/24/2022. We hope to post the Q&A on Tuesday, January 18, 2022. 1/6/2022 Update: Attachment L - HHS Small Business Subcontracting Plan Template, is now uploaded. It was inadvertently omitted from the uploading of Amendment 3-related documents. Amendment #0003: Questions and Answers, and amended Attachment 2 - Labor Categories. See uploaded documents. Amendment #0002: Revises the due date for offeror's questions to Tuesday, December 28, 2021, by 4:30 PM ET. Please review the attached Amendment #00002. Amendment # 0001: Delete Classification -- Partial Set-Aside. This acquisition is a full and open competiltion. No additional revisions are being made under Amendment # 00001. RFQ 75F40122Q00001 Patent Legal Services This contract is to acquire Patent Legal Services that support the entire patent life cycle and provide protection for FDA-owned intellectual property across FDA's Technologies. Patent Legal Services acquired under this contract consist of pre-grant prosecution activities such as patent search services, patent opinions, patent prosecution services, patent litigation, petitions, ancillary patent services and patent fee payment services for both domestic and foreign patent filings. FDA also requires legal services that support contested proceedings and Post-grant activities such as proceedings conducted by the Patent Trial and Appeal Board, Ex-Parte, Inter-Partes Review, covered business method reviews, post-grant review, interference, and licensing consultation. Such post grant services also include reissue, reexamination and interference activities and opposition activities conducted before foreign patent offices. See Attached Combined Synopsis Solicitation: RFQ 75F40122Q00001 Patent Legal Services. Contacts: Kimberly.Davis@fda.hhs.gov; James.Whitt@fda.hhs.gov